Loading
QLC5508 is an experimental antibody-drug conjugate from Qilu Pharmaceutical in phase 3 trials for oesophageal cancer, prostate cancer and non-small-cell lung cancer, aimed at B7-H3.
QLC5508 (MHB088C) is an antibody-drug conjugate developed by Qilu Pharmaceutical and Minghui Pharmaceutical (Hangzhou). Its target is B7-H3. ClinicalTrials.gov describes the intervention as: B7H3 ADC; QLC5508 will be administered by injection at the dose and dosing frequency specified in the protocol. It is the investigational product in 6 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT07463573 (QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Oesophageal Squamous Cell Carcinoma) and NCT06954246 (A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer), in oesophageal cancer, prostate cancer and non-small-cell lung cancer. The largest, NCT07102004, plans to enrol 515 participants with primary completion was scheduled for 2026-07 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Antibody-drug conjugate directed at B7-H3, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated. Connects to B7-H3.
1.QLC5508's antibody arm binds B7-H3 on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"QLC5508" OR ABSTRACT:"QLC5508" OR TITLE:"MHB088C" OR ABSTRACT:"MHB088C") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about QLC5508, not a curated reading list.
Shares A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer, Qilu Pharmaceutical, Prostate cancer and the tag pipeline.
Shares A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors, A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Sm, Qilu Pharmaceutical, Non-small-cell lung cancer and the tag pipeline.
Shares Minghui Pharmaceutical, Prostate cancer and the tag pipeline.
Shares A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors, Qilu Pharmaceutical, Non-small-cell lung cancer and the tag pipeline.
Shares B7-H3, Prostate cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Minghui Pharmaceutical and the tag pipeline.
Shares Minghui Pharmaceutical and the tag pipeline.
Shares Minghui Pharmaceutical and the tag pipeline.